In particular, strategies aimed at limiting VEGF signaling through rAAV-mediated expression of soluble fms-like tyrosine kinase 1 (sFLT-1) have demonstrated some degree of efficacy in limiting CNV formation in pre-clinical animal models of wet AMD and have now progressed to Phase I/II clinical trials38–41. Here, VEGFA is linked to wet macular degeneration.